Clinical Trial Update: Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating arbaclofen for social withdrawal in autism spectrum disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• Arbaclofen (arbaclofen)

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Autism Spectrum Disorders | Phase 2 | Status: COMPLETED